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PRIMER-EXTENSION BASED METHOD FOR 
THE GENERATION OF SIRNA/MIRNA 
EXPRESSION VECTORS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit of U.S. provisional patent 
application 60/956,619, filed Aug. 17, 2007, the complete 
contents of which is hereby incorporated by reference. 
STATEMENT REGARDING FEDERALLY 
SPONSORED RESEARCH OR DEVELOPMENT 
This invention was made with govermnent support under 
contracts ROI HL-052146, ROI HL-071628 and ROI 
HL-083188 awarded by the National Institute of Health. The 
govermnent has certain rights in the invention. 
SEQUENCE LISTING 
This application includes as the Sequence Listing the com-
plete contents of the accompanying text file "Sequence.txt", 
created Aug. 13, 2008, containing 4,571 bytes, hereby incor-
porated by reference. 
BACKGROUND 
Over the last few years, RNA interference (RNAi) has 
emerged as an effective method of silencing gene expression 
in a variety of organisms, particularly mammals (19). Among 
its many applications are the characterization and regulation 
of gene function, analysis of signaling pathway and target 
validation. Another intriguing aspect ofRNAi is its potential 
therapeutic value. The RNAi response in mammalian cells 
mediated by dsRNA is a well-defined two-step process. Ini-
tially, the dsRNA is cleaved into small interfering RNAs 
(siRNA) of approximately 19 to 25 nucleotide (nt) by an 
RNase III-like enzyme known as Dicer. Then, the siRNA is 
incorporated into a RNA-induced silencing complex (RISC), 
which destroys mRNAs that are homologous to the integral 
siRNA ( 45). In mammalian cells, interferon-mediated antivi-
ral response to long dsRNA (>30 bp) causes the global shut-
down of protein synthesis. To bypass this non-specific effect, 
small siRNA (<30 nt) has been used to induce reliable and 
efficient knockdown of target genes while evading the inter-
feron response (13). 
Gene silencing can be induced by direct transfection of 
cells with chemically synthesized (13) or in vitro transcribed 
siRNA (24, 30, 33). Alternatively, it can be obtained by trans-
fecting a plasmid or transducing a viral vector encoding a 
short hairpin RNA (shRNA) driven by a RNA polymerase 
(pol) III promoter, including U6, Hl, 7SK and tRNA promot-
2 
be obtained in vivo by using a DNA-based shRNA vector. 
Fourth, vector-based RNAi can be used to rapidly generate 
knockdown/knockout mice, which would be useful models 
for unraveling the genetic roots of many human diseases. In 
5 the past few years, various groups, including our own, have 
developed systems for vector-mediated specific RNAi in 
mammalian cells. Regarding the construction of shRNA vec-
tor, the most common strategy requires the synthesis, anneal-
ing and ligation of two complementary oligonucleotides 
10 encoding a desired shRNA target sequence into an expression 
vector (32). The small DNA inserts prepared from the 
annealed oligonucleotides consist of 19-29 nt complimentary 
to the target sequence followed by its antisense sequence 
placed in the inverse orientation, separated by a spacer to 
15 make the hairpin loop. A terminal signal of 5-6 T and the 
corresponding overhangs for cloning are also included. 
Although this method is quick, it often suffers from mutation 
problems (32, 37). Typically, 20-50% of cloned shRNA con-
structs contain significant mutations as determined by DNA 
20 sequencing. The mutation frequency is close to 75% when the 
desired siRNA sequence is 29 nt in size (37). The unreliability 
of this method is in part due to the errors in the synthesis of 
long oligonucleotides (>50-mer). To verify the shRNA con-
structs that do not contain any errors, it was advised to pick up 
25 at least a few bacterial colonies for sequencing (38). Obvi-
ously, this process is time-consuming and costly. Another 
strategy that fewer people use in constructing shRNA vector 
is a PCR approach. With this approach, a promoter sequence 
serves as the template with an upstream primer that is comple-
30 mentary to the 5' end of the promoter region, and a down-
stream primer containing the desired hairpin siRNA target 
sequence and a region that is complementary to the 3' end of 
the promoter (22). Although it allows successful amplifica-
tion of hairpin structures in a single amplification step, the 
35 correct amplicon production is critically dependent upon on 
the quality of downstream primer. For this reason, the method 
requires costly purification of the long downstream primer. 
shRNA expression vector can also be produced from target 
cDNA by enzymatic digestion (30). However, this method 
40 involves a multi-step process and may increase off-target 
effects. Recently, McIntyre and Fanning (31) reported an 
alternative approach to construct shRNA expression vector 
through the primer extension using a long template oligo-
nucleotide and a short universal primer. The mutation rate 
45 was decreased by using DNA polymerase Phi29. However, 
the method still utilizes one long template oligonucleotide 
(72 nt if the siRNA sequence is 21 nt), which is not a trivial 
task. The strong secondary structure within this long oligo-
nucleotide led to the difficulty of chain elongation. Kim et al. 
50 (25) described another approach of generating shRNA with 
short oligonucleotides. It is more cost-effective and less error-
prone, but the shRNA vector coming from this method may 
be less potent because the loop sequences must be palindro-
mic. ers (5, 15, 38, 43), or a pol II promoter such as CMV or SP-C 
(16, 42). shRNAs consist of short inverted repeats separated 55 
by a small loop sequence and is rapidly processed by the 
cellular machinery into 19-22 nt siRNA, thereby suppressing 
the target gene expression. Though siRNA and shRNA elicit 
comparable results in RNAi experiments, the use of shRNA 
expression vectors is more appealing with several advantages 60 
over chemically synthesized siRNA. First, the use of plasmid 
As can be seen, current methods of constructing shRNA 
vectors are costly and often suffer from mutation problem 
during synthesis. 
SUMMARY OF THE INVENTION 
In the present disclosure, we report novel methods to 
design and produce shRNA expression vectors or templates 
with high efficiency. A major improvement was using shorter 
(s50-nt) primers to generate a shRNA insert using primer 
extension. We found that the construction of shRNA expres-
sion vectors with this new approach dramatically reduces the 
occurrence of mutations. The methods allow the production 
to express shRNA is fairly inexpensive and has been shown to 
achieve long-term target gene suppression in cells and whole 
organisms. Second, the efficient delivery and stable integra-
tion of these shRNA expression cassettes into the host 65 
genome can be efficiently achieved by using various viral 
systems. Third, inducible or cell-specific gene silencing can 
US 8,795,988 B2 
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of many shRNA vectors in parallel at a greatly reduced cost 
with high efficacy.Using this method, a micro RNA (miRNA) 
overexpression library was constructed which facilitates the 
expression of 254 matured miRNAs that were candidates for 
involvement in human Survivin transcriptional regulation. 5 
High-throughput screening inA549 cells was performed. The 
results showed that the expression of several of the miRNAs 
(miR-192, 199a, 19a, 20a, 213 and 371) caused activation of 
the Survivin promoter while expression of several other miR-
NAs (miR-302b*, 34a, 98,381,463 and 471) decreased Sur- 10 
vivin promoter activity. These results show that the shRNA 
vectors of the invention can be successfully used to generate 
shRNAs (e.g. mature miRNAs) within cells and that the 
shRNA so-produced successfully modulates or regulates 
gene activity. The invention provides methods of making 15 
shRNA vectors, methods of making shRNA using such vec-
tors, and method of modulating gene activity by expressing 
shRNA from the shRNA vectors within cells or tissues. 
4 
fectamine 2000 with pGL3-miR-375, a firefly luciferase 
reporter construct containing one target site for miR-3 7 5, and 
miR-375, miR-21 expression vector or a GFP control vector 
expressing unrelated shRNA (Con). Twenty-four hours post-
transfection, the cells were assayed for dual-luciferase activi-
ties. 
FIG. 6A-G. Screening for miRNAs involved in the regula-
tion of human Survivin promoter activity inA549 cells. A549 
cells were plated 25000 cells/well in 96-well plates. After 
overnight culture, cells were transfected with 25 ng of pSur-
vivin-F. Luc reporter gene vector, 2.5 ng of pRL-TK normal-
ization vector and 75 ng of each miRNA expression vector 
using Lipofectamine 2000. Forty-eight hours post-transfec-
tion, cells were assayed for dual-luciferase activities. The 
relative luciferase activities were normalized by a GFP con-
trol vector expressing unrelated shRNA (shCon). The results 
shown are means±S.D. (n=3). (G), Specificity ofmiRNAs in 
the promoter activity assay. Human SP-B promoter-driven 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Overview of the primer extension method used to 
produce short hairpin DNA inserts for the construction of 
shRNA vector. Step 1, Rule of two primer design; Step 2, 
Primer annealing and extension; Step 3, Digestion of primer 
extension product to leave the overhang sequences of 
5'-CACC and 5'-AAAA for the ligation with the pENTR/U6 
vector. 
20 firefly luciferase vector (pSP-B-F.Luc) was co-transfected 
with the pRL-TK vector and a miRNA over-expression vec-
tor. Forty-eight hours post-transfection, cells were assayed 
for dual-luciferase activities. The relative firefly luciferase 
activity in each treatment was normalized by a control vector 
25 expressing unrelated shRNA (shCon). The error bars indi-
cated the standard deviation, n=3 in each group. 
FIG. 2. Primer extension products by three different DNA 
polymerases. 5 µI of reaction products were analyzed on a 30 
1.5% agarose gel in SB buffer. The products of76 bp small 
DNAs were indicated by arrowhead. Lane 1, Kienow Frag-
ment; Lane 2, Bst DNA polymerase large fragment; Lane 3, 
Taq DNA polymerase; Lane M, 100 bp DNA ladder. 
FIG. 3A-C. Effect of loop sequences on primer extension 35 
products and silencing efficiency. (A) The putative shRNA 
structures with 4 different loop sequences. (B) Four extension 
products with different loops by using Kienow fragment were 
analyzed on a 1.5% agarose gel in SB buffer. Lane M, 100 bp 
DNA ladder; Lane 1, 9-nt loop sequence of 5'-TTCAA- 40 
GAGA-3'; Lane 2, 10-nt loop sequence of 5'-CTTCCT-
GTCA-3' (SEQ ID NO: 1); Lane 3, 11-nt loop sequence of 
5'-GTGTGCTGTCC-3' (SEQ ID NO: 2); Lane 4, 19-nt loop 
sequence of 5'-TAGTGAAGCCACAGATGTA-3' (SEQ ID 
NO: 3; annealing region was underlined); Lane 5, negative 45 
control of two primers before extension. (C) Silencing of 
EGFP by vector-based shEGFP with different loop struc-
tures. 293A cells were co-transfected with U6-driven 
shEGFP417 with 4 different loop sequences and pDsRed2-
Cl for normalization). The pU6-shFL vector expressing a 50 
shRNA against firefly luciferase (shCon) was used as a nega-
tive control. EGFP expression was shown as a percentage of 
shCon (means±SD, n=3). 
FIG. 4. Diagrams for miR-30-based shRNA template gen-
eration via the primer extension method. To reduce cost in 55 
primer synthesis, the last 10-nt sequences (5'-GAAGCCA-
CAG-3', SEQ ID NO: 4) within the miR30 loop was designed 
as the annealing region. An Eco31 I restriction site with three 
protection bases was added at the 5'-end of each oligonucle-
otide. The cloning vector of pENTR/CMV-EGFP-miR-30 60 
was generated by inserting a primary miR-30 fragment con-
taining two Eco31 I sites between the EGFP coding sequence 
and the SV 40 poly A terminal region in pENTR/CMV-EGFP 
vector. 
FIGS. 7A-C. Schematic representation of method for pre-
paring shRNA. A, annealing and filling in steps; B, cleaving 
and insertion steps; C, transcription and folding steps. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
As described, over the last few years, RNA interference 
(RNAi) has emerged as an effective method of silencing gene 
expression in a variety of organisms, particularly mammal 
(16). Among its many applications are the characterization 
and regulation of gene function, signaling pathway analysis 
and target validation. Another intriguing aspect ofRNAi is its 
potential therapeutic value. The RNAi response in mamma-
lian cells mediated by dsRNA is a well-defined two-step 
process. Initially, the dsRNA is cleaved into small interfering 
RNAs (siRNA) of approximately 19 to 25 nucleotide (nt) by 
an RN ase III-like enzyme known as Dicer. Then, the siRNA is 
incorporated into a RNA-induced silencing complex (RISC), 
which destroys mRNAs that are homologous to the integral 
siRNA (38). In manimalian cells, interferon-mediated antivi-
ral response to long dsRNA (> 30 bp) causes the global shut-
down of protein synthesis. To bypass this non-specific effect, 
introducing small siRNA (<30 nt) has been used to induce 
reliable and efficient knockdown of target genes while evad-
ing the interferon response (10). 
The present invention provides a new method of generating 
shRNA DNA vectors or templates for in vitro transcription. 
The method differs from prior art methods, for example, 
because the loop sequence of the shRNA is defined by two 
annealing oligonucleotides that are less than about 50 nt long. 
Since these short oligonucleotides extension reaction are less 
than 50 nt, and preferably less that about 45 nt long, the rate 
of mutation is sharply decreased and the accuracy of positive 
clones is dramatically improved. The method allows for the 
production of many shRNA vectors in parallel at a greatly 
reduced cost with high efficacy. By using the loop sequence-
mediated primer extension method of the invention, a 
FIG. 5. Effect of miRNA expression on miRNA target-
luciferase activity. 293A cells were cultured in 24-well plates. 
After overnight culture, cells were transfected using Lipa-
65 microRNA (miRNA) overexpression library was constructed 
that permitted the discovery of miRNAs that regulate pro-
moter activity in the mammalian Survivin gene. 
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In one embodiment, the invention provides expression vec-
tors encoding shRNA molecules of interest. Such vectors are 
typically plasmids, although those of skill in the art will 
recognize that other types of expression vectors may also be 
employed, including but not limited to various viral-based 
vectors such as adenoviral, lentiviral, adeno-associated viral, 
and retroviral vectors; as well as various plasmid-based vec-
tors and other vectors such as baculovirus, phage, phagemids, 
cosmids, phosmids, bacterial artificial chromosomes, 
Pl-based artificial chromosomes, yeast plasmids, yeast arti-
ficial chromosomes, etc. The vectors of the invention mediate 
the expression or over-expression (i.e. expression that would 
not occur if the vector was not present) of the shRNA mol-
ecules that they encode. Further, more than one shRNA may 
6 
ment 22), 15 ( complementary to element 11) and 25 ( comple-
mentary to element 21), to form double strand DNA structure 
40. Those of skill in the art will recognize that various proof-
reading polymerases and enhancing agents may be included 
5 in this reaction in order to increase accuracy. Cleavage of ds 
DNA structure 40 using an appropriate restriction enzyme 
(i.e. restriction enzymes that recognize and cleave elements 
11 and 21) results in production of structure 50 which con-
tains 5' overhangs 51 and 52. Structure 50 can then readily be 
10 inserted into an expression vector such as a plasmid that has 
been cleaved or otherwise constructed so as to contain 
complementary overhangs, as is known to those of skill in the 
art. 
be encoded by a single expression vector. The shRNA that is 15 
encoded may function as siRNA, or as miRNA, etc. 
The shRNA expression vectors of the invention may also 
include other features, including but not limited to: reporter 
genes such as Green fluorescent Protein (GFP), Lacz or red 
fluorescent protein; and various promoter (inducible or non-
inducible) such as, for example, the Survivin promoter, Hl, 
U6, 7SK, etc., to drive transcription of the shRNA and/or of 
other genes located in the vector. Further, the vector may be 
The vectors of the invention are made by designing and 
preparing two oligonucleotide primers ( designated herein as 
the first and second primers, or as Pl and P2) that undergo 
annealing, conversion to double strand ( ds) DNA, cleavage 20 
with restriction enzymes, and insertion into a suitable expres-
sion vector. Significantly, in order to minimize errors during 
primer synthesis, the length of each of the two primers is less 
than about 50 nucleotides (nts), and preferably is less than 
about 45 nts. Such primers include those with a total length of, 25 
for example, 50, 49, 48, 47, 46, or 45 or fewer nts. In order to 
accommodate the three basic elements that are encoded by 
the primers (described in detail below), the minimum length 
of the primers will be in the range of from about 36 to about 
45 nts, and usually such primers will be at least about 36 nts 30 
in length. The two primers that are used in the preparation of 
a shRNA expression vector of the invention may both be the 
same length, or may differ in total length 
designed to contain, for example, tissue or cell specific pro-
moters which cause transcription of the shRNA in a tissue or 
cell-specific manner. Within the expression vector, the 
sequences encoding one or more shRNA molecules are 
expressibly linked to a promoter, i.e. they are located within 
the expression vector in a manner that allows transcription of 
the shRNA to be initiated or driven by the promoter in a 
manner that produces functional shRNA. Functional shRNA 
is shRNA that attains a secondary structure ( e.g. via base 
pairing, folding, etc.) that is capable ofbiological activity, i.e. 
of regulating or modulating gene activity, when suitable 
homologous or complementary nucleotide sequences are 
present ( e.g. within a cell) and is allowed to interact with the 
shRNA. 
Transcription of vector 60 by techniques that are known to 
those of skill in the art produces single strand RNA 100. 
ssRNA 100 comprises sequence 124, which corresponds to 
element 22 of original primer 20, sequence 112, which cor-
This procedure of preparing shRNA expression vectors 
using a two-primer design is represented schematically in 35 
FIGS. 7A-B, where primers 10 and 20 are indicated. With 
reference to FIG. 7A, primer 10 comprises at least three 
elements: element 11 which is or which includes a restriction 
enzyme recognition sequence; element 12, which is a 
sequence encoding the sense strand of an RNA stem struc-
ture; and element 13, which encodes an RNA loop structure. 
Primer 20 also comprises three elements: element 21 is or 
includes a restriction enzyme recognition sequence; element 
40 responds to element 12 of original primer 10, and sequence 
113, which corresponds to element 13 of primer 10. Because 
elements 12 and 22 of primers 10 and 20 are identical, after 
the steps of annealing, filling in, cleaving, insertion and tran-
scription, sequences 124 and 112 are complementary to one 22 is a sequence encoding the sense strand of an RNA stem 
structure and is the same as (i.e. is identical to) element 12 of 
primer 10; and element 23, which contains sequences that are 
complementary to the sequence of element 13. Therefore, 
when primers 10 and 20 contact one another under suitable 
conditions ( conditions that allow base pairing to take place), 
segments 13 and 23 will anneal. This step of annealing results 
in the production of annealed structure 3 0. Annealed structure 
30 is single stranded, except in the region of complementary 
base paired elements 13 and 23. 
In addition, 10 and 20 primers 10 and/or 20 may include 
short optional protection sequences 5' and adjacent to one or 
both of elements 11 and 21. Such protection sequences are 
preferably of about 2 to about 5 nts in length. The function of 
a protection sequence is to increase the efficiency of restric-
tion enzyme digestion. 
The single strand portions or sections of annealed structure 
30 are then "filled in" i.e. converted to double strand DNA, by 
the action of enzymes which are known to those of skill in the 
art, e.g. using Kienow fragment, Bst DNA polymerase large 
fragment, 9° Nm DNA polymerase, etc. Such enzymes attach 
an appropriate base to each base in a single stranded DNA 
sequence, thereby creating complementary sequences 14 
(complementary to element 12), 24 (complementary to ele-
45 another. Under conditions favorable to RNA base pairing, 
these two segments base pair (anneal) and folded shRNA 
structure 200 is formed. shRNA 200 includes ss loop 113, 
which is not base paired. Transcription reactions may take 
place in vitro or in vivo, in cells or in cell-free translation 
50 systems. 
Those of skill in the art will recognize that, while in this 
schematic representation base pairing between complemen-
tary sequences is depicted as exact (i.e. depicted with no 
unpaired bases) this need not be the case. For example, addi-
55 tional paired or unpaired bases may be present at the 5' or 3' 
end of sequences 112 and/or 124. Such bases, which would 
typically be a maximum of about 5 nts in length, and prefer-
ably shorter, may originate e.g. from the restriction site 
sequences, or be introduced as an artifact of transcription, or 
60 originate from protection sequences, etc. Further, sequences 
112 and 124 need not be completely complementary. For 
example, they may be substantially complementary, based 
paired over most of their length (e.g. more than about 75%, 
and preferably more than 80%, and more preferably more 
65 than 90% of the nts in each of strands 112 and/or 124 are 
base-paired with ant from the opposite, largely complemen-
tary strand). Those of skill in the art will recognize that 
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mismatches in the substantially complementary sequences 
may cause a single strand "bulge" in the stem of the stem-loop 
structure. 
8 
either a single type of shRNA or with multiple shRNAs ( e.g. 
a library) may be carried out in vitro or in vivo, as well as in 
cell-free translation systems. 
The single strand loop of the shRNA is typically from In addition, those of skill in the art will recognize that loop 
113 need not be completely single stranded. In some embodi-
ments, some base pairing within the loop may occur, and 
structures such as bulges or bubbles may be formed within the 
loop. Further, multiple loops may form within a single "loop" 
structure, or cloverleaf structures, etc. may be formed. How-
ever, generally those of skill in the art will recognize that at 
least the first 3' and 5' nucleotides, and usually at least the first 
two 3' and 5' nucleotides adjacent to the stem, will not be 
base-paired, and will define the beginning of the loop seg-
ment of the shRNA. In addition, if there is basepairing within 
the loop, generally fewer than about 20%, and typically fewer 
than about 15%, and more typically fewer than 10% of the 
bases in the loop will be base-paired. 
5 about 3 to about 19 nts in length, and preferably is greater than 
about 7 nts in length. The composition of the loop may be 
selected, for example, from structures that are available in the 
extant literature, or modifications thereof. In other words, the 
loop sequences may be identical to loop sequences that are 
1 o known to occur in nature, or, alternatively, they may be modi-
fied versions of naturally occurring loop sequences. Finally, 
the loop sequences may be designed artificially (i.e. de nova) 
without reference to naturally occurring sequences. In addi-
tion, it is possible to "mix and match" natural or artificial loop 
15 structures with natural or artificial stem structures. 
The primers utilized in the practice of the invention are 
generally single strand DNA primers comprising the nucle-
otides adenine (A), cytosine (C), guanine (G) and thymine 20 
(T), as is well-known to those of skill in the art. 
The primers of the invention comprise at least three ele-
ments: an element that encodes one or more restriction sites; 
and element that encodes RNA loop sequences, and an ele-
ment that encodes an RNA stem-forming sequence. The 25 
primers themselves are typically less than about 50 nts, and 
preferably less than about 45 nts, in length. The sizes of the 
three elements may vary from construct to construct, but will 
generally be as follows: the sequences that contain at least on 
restriction site are from about 6 to about 12 nts in length; the 30 
sequences that encode an RNA loop sequence are generally 
from about 3 to about 19 nts in length, and are preferably 
greater than about 7 nts in length; and the sequences that 
encode an RNA stem sequence are from about 15 to about 25 
nts in length, and preferably from about 19 to about 22 nts in 35 
length. Depending on the construct, the loop structure may be 
about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 
or 20 nts in length. 
Those of skill in the art will recognize that many restriction 
enzymes exist, the corresponding restriction enzyme recog- 40 
nition sites of which may be incorporated into the primers of 
the invention. Preferably, the restriction sites that are used 
produce 3' and/or 5' overhangs upon cleavage with an appro-
priate restriction enzyme. Examples of such restriction 
enzymes include but are not limited to Eco31I, Bspl 19I, 45 
XhoI, EcoRI, ApaI, BamHI, Bg!II, ClaI, HindIII, Sall, XbaI, 
etc. 
Selection of the sequences that are included in the stem 
portion of the shRNA are selected based on the intended use 
The shRNA vectors and shRNA molecules described 
herein contain various nucleic acid sequences that are 
complementary to various other nucleic acid sequences, e.g. 
within the same molecule or structure ( e.g. the stem portion of 
an shRNA, the annealing region of the armealed structure, 
etc.). Those of skill in the art will recognize that due to the 
base-pairing nature of nucleic acids and the ability of a single 
strand of nucleic acid to serve as a template for production of 
a corresponding complementary strand of nucleic acid, which 
in turn may serve as a template for production of another 
complementary strand, a pattern or particular sequence of 
nucleotide bases that is introduced (e.g. in a primer) may be 
passed from one nucleic acid to another during replication, 
extension reactions, amplification, etc. As used herein, 
sequences which are related to one another in this manner 
may be referred to as homologous sequences or correspond-
ing sequences. Such sequences may or may not be comple-
mentary. 
EXAMPLES 
Example 1 
Construction of siRNA/miRNA Expression Vectors 
Using Primer-Extension 
MicroRNAs (miRNA) are single-stranded RNA molecules 
of about 21-23 nucleotides in length, which regulate gene 
expression. miRNAs are encoded by genes that are tran-
scribed from DNA but not translated into protein ( non-coding 
RNA); instead they are processed from primary transcripts 
known as pri-miRNA to short stem-loop structures called 
pre-miRNA and finally to functional miRNA. Mature 
miRNA molecules are partially complementary to one or 
50 more messenger RNA (mRNA) molecules, and their main 
function is to downregulate gene expression. In this example, 
a library of shRNA molecules comprising sequences of 
known miRNAs was constructed and used in a high through-
put screening format to test the ability of each shRNA/ 
of the shRNA. Generally, sequences in the stem are comple-
mentary to a sense and antisense DNA of interest, such as a 
gene, and are from about 15 to 25 nts in length, preferably 
from about 19 to about 22 nts in length, and more preferably 
from about 20 to about 21 nts in length. By base-pairing with 
the gene, transcription of the gene, and thus translation of the 
encoded protein) is prevented. In this marmer, shRNA mol-
ecules can inhibit expression or activity of a gene of interest 
and the protein it encodes. In one aspect of the invention, an 
array or library of shRNA vectors may economically and 
easily be produced and used to interrogate a cell or cells or 60 
tissues to investigate the effect of the inhibition of one or more 
genes at once, or to investigate the effect of one or more 
shRNAs on one or more genes. For example, such investiga-
tions may be carried out in a high throughput screening for-
mat. Further, such shRNA molecules may mimic naturally 65 
occurring molecules that have or contain stem loop struc-
tures, such as microRNA (miRNA). Inhibition reactions with 
55 miRNA in the library to influence the activity of the Survivin 
promoter. 
Materials and Methods 
Construction of shRNA expression vector using primer 
extension. Here, we describe the approach of making a human 
U6 promoter driven shRNA vector with the most recom-
mended loop sequence of 5'-TTCAAGAGA-3'. The entire 
procedure involves the following four steps as shown in FIG. 
1. 
Step 1: Primer design. To make a small DNA fragment 
containing sense-loop-antisense-terminal signal and the cor-
responding cloning sites, two oligonucleotides were designed 
for primer extension. The sequence of upper (P 1) oligonucle-
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otide includes 5'-CCTGGTCTCACACC[G]Nc19_23 l 
TTCAAGAGA-3' (SEQ ID NO:5); the lower oligonucleotide 
includes 5'-CCTGGTCTCAAAAANc19_23 l TCTCTTGAA-
3' (SEQ ID NO: 6). Minimal synthesis oligonucleotides 
(0.025 µM and desalt) were obtained from Sigma Genosys 5 
and re-suspended in TE buffer (10 mM Tris pH 8.0, 1 mM 
EDTA) at the concentration of 50 µM. Since the sizes of all 
oligonucleotides were less than 50-nt, their accuracy during 
the synthesis is guaranteed by the company. 
Step 2: Primer extension. Twenty five picomoles of each 10 
oligonucleotide was used in the extension reaction including 
lx buffer G (Fermentas), 0.2 mM final concentration of 
dNTPs, and 1 unit of Kienow fragment (3'-5') exo-). The 
reaction was carried out at 37° C. for 30 min and then the 15 
Kienow was inactivated at 70° C. for 20 min. 
10 
by DNA sequencing with a mU6 sequencing primer (5'-
ACATGATAGGCTTGGATTTC-3', SEQ ID NO: 15). 
miRNA Library Screen 
The 1.1 kb of Survivin promoter was amplified from 
human genomic DNA with a primer set of 5'-CACCGAGGC-
CGCTGGCCATAGAACCAGAGAAGTGA-3' (SEQ ID 
NO: 16) and 5'-TAACTAGTCCACCTCTGC-
CAACGGGTCCCGCG-3' (SEQ ID NO: 17) and subcloned 
into the previously described pENTR/CMV-EGFP vector 
(16) by switching CMV promoter through Not I and Spe I 
sites. Next, the EGFP fragment was replaced with Firefly 
luciferase, (F. Luc), which was amplified from a pGL3-con-
trol vector (Promega ). The new vector of pSurvivinF.Luc was 
used for co-transfection combined with miRNA vectors and 
the normalization vector, pRL-TK (Promega). As an unre-
lated promoter control, the human SP-B promoter was ampli-
fied from human genomic DNA with the primer set: 5'-CAC-
CGCGGCCGCGTATAGGGCTGTCTGGGA-3' (SEQ ID 
NO: 18) and 5'-GGACTAGTCTGCAGCCTGGGTAC-3' 
(SEQ ID NO: 19). The SP-B promoter-driven F.Luc vector, 
pSP-B-F.Luc was constructed by replacing the Survivin pro-
moter with the SP-B promoter through Not I and Spe I sites. 
A549 human lung cancer cells were grown in F12K medium 
Step 3: Digestion, purification, ligation and transforma-
tion. After heat inactivation of the Kienow Fragment, 5 U of 
Eco31 I (Fermentas) were directly added into the reaction. 
After digestion at 37° C. for 2 hand purification was carried 20 
out using a QIAEX II Gel Extraction Kit (Qiagen). 100 ng of 
purified DNA inserts were ligated into pre-made pENTR/ 
mU6 vector (see below). Positive clones were confirmed by 
automated sequencing using U6-sequencing primer (5'-
GGACTATCATATGCTTACCG-3', SEQ ID NO: 7). 25 (Invitrogen) supplemented with 10% fetal bovine serum. 
Construction of miRNA Overexpression Library Transient transfection of plasmids into overnight cultured 
A549 cells (2.5xl04 cells/well) in 96-well plates was per-
formed for 48 h using Lipofetamine™ 2000 (Invitrogen). The 
transfected DNA mixtures (102.5 ng/well) contained 25 ng of 
30 pSurvivin-F.Luc, 2.5 ng of pRL-TK and 75 ng of miRNA 
over-expression vector. After 2 days of transfection, 10 of 50 
µI of total cell lysate were used for determining luciferase 
activities by a luminometer and dual luciferase assay kit 
The mU6 promoter was amplified from the pSilencer 1.0 
vector (Ambion) with the primers 5'-CACCGCGGATC-
GATCCGACGCCGCCATCTCTA-3' (SEQ ID NO: 8) and 
5'-CTTCGAAGAATTCCCGGGTCTCTCAAA-
CAAGGCTTTTCTCCAA-3' (SEQ ID NO: 9). The PCR 
products were directly cloned into the pENTR/D-Topo vector 
(Invitrogen), resulting in a pmU6 vector. Four restriction 
sites, including Bsp119 I, EcoR I, Sma I, and Eco31 I were 
introduced at the 3'-end of the mU6 promoter. For the conve- 35 
nience of monitoring transfection efficiency or determining 
virus titer, a CMV-driven EGFP expression cassette was 
introduced downstream of the mU6 promoter through 
Bsp119 I-Ase I sites (Ase I is in the pENTR vector). This 
resulted in a ready-to-use vector, pEGFP/mU6. Digestion of 40 
the pEGFP/mU6 vector with EcoR31 I and Bsp119 I left 
CAAA and CG 5'-overhangs, respectively. With an aim of 
over-expressing microRNA sequences in mammalian cells 
for functional screening, we selected 270 mature miRNA 
sequences in mammalian cells for a functional screen, 254 45 
mature miRNA sequences were selected from the miRBase 
database located at microrna.sanger.ac.uk. A vector featuring 
a short hairpin microRNA (miRNA) structure was con-
structed. Similar to the construction of the RNAi vector, the 
above-described primer extension method was used to con- 50 
struct a DNA vector expression matured miRNA sense and its 
antisense sequences in the form of short hairpin RNA mol-
ecules. The 9-nt loop 5'-TTCAAGAGA-3' was replaced by a 
10-nt loop sequence, 5'-CTTCCTGTCA-3' (SEQ ID NO: 
10). The Pl oligonucleotide contained sequence 5'-CAAG- 55 
GTCTCATTTG (SEQ ID NO: 11 ), the mature-miRNA sense 
sequence 5'-CTTCCTGTCA-3' (SEQ ID NO: 12); the P2 
oligonucleotide includes 5'-GAGTTCGAAAAA-3' (SEQ ID 
NO: 13) mature-miRNA sense sequence 5'-TGACAG-
GAAG-3' (SEQ ID NO: 14). As two restriction site ofEco31 60 
I and Bspl 19 I, were included in the Pl and P2 oligonucle-
otides, respectively, (see underlining in FIG. 1, Step 1), the 
extension product resulted in 5'-TTTG and 5'-GC overhangs 
after digestion with Eco31 I and Bsp119 I, and could be 
directly inserted into the pEGFP/mU6 vector via correspond- 65 
ing sites. The ligation mixtures were transformed into chemi-
cally competent cells of GT! 16. All the inserts were verified 
(Promega ). The luciferase activities were normalized against 
the activity of pRL-TK control vector. 
RNAi EGFP suppression assays. 293A cells were cultured 
in 24-well plates until >90% confluence. The cells were trans-
fected with 50 ng ofrespective target pCMV-EGFP plasmid 
and 250 ng of shRNA expression vector by using Lip-
fectamine 2000 reagent (Invitrogen). To normalize the trans-
fection efficiency, 50 ng of a red fluorescent protein reporter 
plasmid (pDsRed2-Cl vector, Clonetech) were co-trans-
fected with each sample (12, 41). After 48 h, the cells were 
washed twice with PBS, 250 µI of lysis buffer was added to 
each well and the cells were freeze-thawed 3-times. After 
centrifugation for 10 min, 5 µI of supernatants were used to 
measure the expression of EGFP and DsRed2, which was 
determined by the FluoroMax 3 fluorometer using Ex=489 
nrn/Em=508 nm and Ex=563 nrn/Em=582 nm, respectively. 
Results and Discussion 
Construction of shRNA Vector 
To validate our approach, we selected a 21-nt siRNA 
sequence against the coding region ofEGFP at the position of 
417 to 437 (5'-GCACAAGCTGGAGTACAACTA-3', SEQ 
ID NO: 20). The reaction was carried out with 25 pmol of 
each primer and three DNA polymerases ranging in concen-
tration from 0.5 U to 2.5 U in 20 µI of total volume. Primer 
extension products were analyzed on 1.5% Sodium Boric 
acid (SB) agarose gels. As shown in FIG. 2, primer extension 
with either Kienow Fragment (3'-5' exo-) or Bst DNA poly-
merase large fragment occurs effectively with a sharp DNA 
band of76-bp in size. Taq DNA polymerase is less efficient, 
probably because the extension temperature of72° C. is too 
high for primer annealing. When we checked the amount of 
each polymerase in a 20 µI of reaction volume, we found that 
1.0 U of each polymerase is sufficient to produce enough 
DNA products. 
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Because the primer extension products need to be digested 
with a restriction enzyme before cloning into the shRNA 
vector, we therefore generated those extension products by 
using Kienow Fragment, which is active in all restriction 
enzyme reaction buffers. 5 U ofEco31 I was then added to the 5 
reaction mixtures that were heated at 75° C. for 20 min to 
oligonucleotides at small scale, only 10-nt in loop 4 (itali-
cized) were selected as the annealing sequence in the exten-
sion reaction. However, all designs depicted gave successful 
extension products (FIG. 3B). 
To study the possible influence of the loop sequences on the 
RNAi effect, we transfected 293A cells with each construct in 
combination with a homologous target expression plasmid 
pENTR/CMV-EGFP, which encodes EGFP, and with a non-
targeted reporter plasmid pDsRed2-Cl, which encodes the 
inactivate the Kienow Fragment. After allowing the reaction 
to proceed at 3 7° C. for 2-4 h, we purified the Eco31 I digested 
DNA by using a QIAEX II Gel Extraction Kit. The purified 
DNA was ligated into the pre-prepared pENTR/mU6 vector 
and transformed into GTl 16 competent cells. For compari-
son, we also constructed shEGFP vectors by using the con-
ventional method of two longer oligonucleotides. The final 
sequencing results showed that only 2 plasmids out of 40 
samples coming from the primer extension method of the 
invention have mutations (Table 1 ), which is much lower than 
the number of mutations produced using the conventional 
annealed oligonucleotides cloning strategy, in which 32 out 
10 DsRed2 protein for normalization. As shown in FIG. 3C, the 
first three loop sequences have a similar activity in silencing 
EGFP. Human miR-30 (loop 4) mediated RNAi was less 
effective. This result differs from that of a previous study, in 
15 which the expression of HIV-1 specific shRNA through a 
miR-30 precursor stem-loop structure was shown to be 
approximately 80% more effective than loop 2-mediated 
shRNA ( 4 ). Although the reason for this difference is not 
clear, similar results have also been obtained by others (51). of 40 clones had mutations. This result shows that the novel 
method of the invention for producing siRNA/miRNA is sig- 20 
nificantly less error-prone than previously known methods. 
The construction of miR-30-based shRNA libraries, in 
which the shRNAmir inserts were amplified from 97-nt syn-
thesized oligonucleotide templates using two universal prim-
ers, has been reported (6; 41). However, according to those 
reports, only 25 to 60% of the clones have correct shRNA 
siRNA Loop sequence 
length (5' -3') 
21 
21 
21 
TTCAAGAGA 
CTTCCTGTCA 
(SEQ ID NO, 1) 
GTGTGCTGTCC 
(SEQ ID NO, 2) 
Construction 
method 
Annealed 
oligos 
Primer-
Extension 
Annealed 
oligos 
Primer-
Extension 
Annealed 
oligos 
Primer-
Extension 
21 TAGTGAAGCCACAGATGTA Annealed 
(SEQ ID NO, 3) oligos 
Primer-
Extension 
Mutation 
(out of 
10 plasmid) 
3 
2 
3 
1 
4 
1 
Table 1: Sequencing evaluation of shRNA vectors generated 
by primer-extension with two short oligos or by traditional 
method with two longer annealed oligos. 10 Plasmids from 
each group were randomly picked for DNA sequencing with 
U6 sequencing primer. 
25 sequences even when a combination of thermostable proof-
reading polymerases and PCR-enhancing agents was used. 
To see whether our primer-extension method can be used to 
construct this type of shRNA vector, we have developed a new 
vector with several notable features. First, we separately 
30 amplified two flanking sequences (each 125 bp) ofmiR-30 
from human genomic DNA by PCR. A Eco31 I restriction site 
and 15-nt overlap sequences were introduced at the 3'-end of 
the left flanking sequence and the 5'-end of the right flanking 
sequences. A primary miR-30-based DNA fragment contain-
35 ing two Eco31 I sites was generated by overlap PCR and 
cloned into a pENTR/CMV-EGFP vector between the EGFP 
coding region and SV 40 terminal sequences, resulting in a 
new pENTR/CMV-EGFP-miR-30 vector. Digestion of 
pENTR/CMV-EGFP-miR-30 vector with Eco31 I left 
40 5'-CGCT and 5'-TGCC-overhangs that allowed ligation to the 
5'-AGCG and 5'-GGCA overhangs ofEco31 I-digestedmiR-
30-based shRNA inserts. For the preparation of shRNA 
inserts, two oligonucleotides (-50-nt in length) were 
designed and used in an extension reaction based on the 10-nt 
45 overlap region as shown in FIG. 4. The advantages of this 
primer-extension method in constructing miR-30-based 
shRNA vectors, compared to other methods (6), include: 
lower cost in synthesizing short oligonucleotides; elimination 
of the need for PCR amplification; no need for DNA purifi-As this present method is based on loop sequence for the 
annealing of two primers, the selection of a loop sequence is 
the key of this procedure. In DNA-based RNAi studies, a 
short loop sequence is necessary for construction of shRNA 
expression vectors. Up to now, more than 20 different loop 
sequences, ranging in size (length) from 3-nt to 19-nt, have 
been reported. For example, Paul et al. used a 4-nt, 5'-UUCG- 55 
3', tetra nucleotide sequence (38); Sui et al. used 5'-CTC-
GAG-3' as a loop sequence (43); Agami's group uses a 9-nt 
loop sequence, 5'-TTCAAGAGA-3', (5). The loop sequence 
appears to somewhat influence the RNAi effect, To ensure the 
efficient annealing of two primers, we recommend using 60 
>7-nt loop sequence. In this report, we examined extension 
reactions carried out with four different loop sequences as 
follows: 8-nt of 5'-CTTGCTTC-3' (loop 1), 9-nt of 
5'-TTCAAGAGA-3' (loop 2), 10-nt of 5'-CTTCCTGTCA-3' 
(loop 3, SEQ ID NO: 1) and 19-nt sequence of 5'-TAGT- 65 
GAAGCCACAGATGTA-3' (loop 4, SEQ ID NO: 3) (FIG. 
3A). To reduce the primer length during the synthesis of each 
50 cation before restriction enzyme digestion; and no need to 
introduce two artificial restriction sites within the miR-30 
flanking sequences. Therefore, the resulting primary miRNA 
sequences are more similar to the original pri-miR-30 with 
the shRNA sequences being 90% correct, a much higher 
percentage than was achieved using other methods. 
Construction of miRNA Overexpression Library 
MiRNAs are endogenous approximately 22 nt RNAs that 
play important regulatory roles in animals and plants by tar-
geting mRNAs for cleavage or translational repression 
through components shared with the RNAi pathway (3; 27; 
48). Hundreds of miRNAs have been found in animals, plants 
and viruses. Over-expression of miRNA may facilitate the 
study of their normal functions and permit effective RNAi in 
vivo. Three different methods have been used to over-express 
miRNA, including chemically synthesized mimic miRNA 
(18), vector-based matured short-hairpin miRNA (50) or 
flanking sequence-included primary miRNA ( 47). 
US 8,795,988 B2 
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that changed Survivin promoter activity by >2-fold was con-
sidered as a hit (i.e. a positive result). Each transfection was 
performed in three replicates and the results are represented in 
FIG. 6A-F. miRNAs that had error bars inside the cutoff were 
To test the activity of miRNA expression vectors, we first 
constructed a F. luc reporter vector with the miRNA-binding 
site for miR-3 7 5. The binding site was made by annealing two 
short oligonucleotides containing the miR-375 binding site 
and inserting into the pGL3 vector at the Xba I restriction site, 
which is located between the F. luc gene and SV40 polyA 
terminal sequence. We tested the effect of miR-375 over-
expression on suppression of gene expression by co-trans-
fecting the miRNA over-expression vector, the F. luc reporter 
vector bearing the miR-375-binding site, and a transfection 10 
normalization vector, pRL-TK. Using a dual-luciferase assay, 
5 not included as hits. Using these criteria, we identified 6 
miRNAs that activated the Survivin promoter activity in 
A549 cells (miR-192, 199a, 19a, 20a, 213, and 371) and 6 
miRNA that decreased Survivin promoter activity (miR-
302b*, 34a, 98, 471, 381 and 463). 
To address the specificity of the effects ofmiRNAs on the 
Survivin promoter assay, an rm-related control promoter, 
SP-B promoter, was tested to see whether the 12 identified 
miRNAs affect the SP-B promoter activity in A549 cells. 
SP-Bis a surfactant protein involved in lung surfactant func-
we found that the specific inhibition of the F. luc reporter gene 
was only observed in the cells over-expressing miR-375, not 
miR-21 (FIG. 5), indicating that short-hairpin-basedmiRNA 
vectors can be used to express functional miRNAs. 
By using the primer-extension method, we constructed a 
miRNA library, which facilitates the expression of 254 
matured miRNA sequences with the following features: (1) 
the mU6 promoter was selected to drive the expression of 
short-hairpin miRNA; (2) al 0-nt loop sequence of 5'-CTTC-
CTGTCA-3' (SEQ ID NO: 1) was used for primer extension; 
(3) 5'-overlap sequences (5'-TTTG-3' and 5'-GC-3') for liga-
tion were created by double digestion of Eco31 I and Bsp 119 
15 tion. Compared to the pEGFP/mU6-shCon vector, most of 
miRNAs did not change the expression of SP-B promoter-
driven F. luc (FIG. 6G). Only miR-471, which down-regu-
lated the Survivin promoter activity, modestly increased the 
SP-B promoter activity. This result suggests that the observed 
20 effects of miRNAs on the F. luc expression are due to the 
promoter activity, but are not due to a direct effect on the F. luc 
I; and (4) the EGFP reporter gene was included in the vector 
to easily track the transfection efficiency. Upon sequencing 25 
all of the plasmids, we found that only 17 out of254 plasmids 
( 6. 7%) had mutations, further supporting the high fidelity in 
constructing shRNA vectors with the primer extension 
method of the invention. We estimate that this method could 
save more than 65% of the cost of methods that require 30 
oligonucleotide synthesis, plasmid preparation and DNA 
sequencing. 
High-Throughput Screening of miRNA Involved in Sur-
vivin Promoter Activity 
gene. 
miRNAs are normally targeted to the 3'-UTR of a gene. In 
our experimental design, the 3'-UTR of Survivin was not 
included in the reporter construct. The effects of miRNAs on 
the Survivin promoter activity are likely because of the inhi-
bition of Survivin transcriptional activators and repressors or 
protein(s) regulating those transcriptional factors. E2Fs pro-
mote cell death when overexpressed or when activated in 
response to DNA damage (34). Induction of apoptosis is a 
unique property ofE2Fl, E2F2 and E2F3 (11). It has been 
reported that E2Fs are involved in the Survivin transcriptional 
regulation, because the Survivin promoter contains an E2F-
like binding element. Recent studies indicate that E2Fl is a 
Survivin is a member of the apoptosis inhibitor family of 
proteins. It is implicated in two key biological events: control 
of cell proliferation and regulation of cell lifespan (29). The 
expression of Survivin is noted in many common tumor types 
but not in normal adult tissues (1; 2). Over-expression of 
Survivin inhibits apoptosis and promotes cancer cell survival 
(17). The inhibition ofSurvivin expression induces cell death 
35 validated target of miR-17 and miR-20a (36). miR-20a also 
regulates E2F2 and E2F3 via the binding sites in the 3'-UTR 
of their respective mRNAs ( 44). Therefore, it is possible that 
the activation ofSurvivin promoter activity by miR-20a may 
be mediated through the depression of E2F transcriptional 
40 factors. 
A very interesting finding is that two miRNAs (miR-19 and 
miR-20) that activate the Survivin promoter belong to the 
miR-17-92 cluster. The miR-17-92 cluster is composed of 
seven miRNAs (miR-17-5p, 18, 19a, 20, 19b-l, 92-1 and 
by apoptosis (28; 39). Survivin gene expression in cancer 
tissue appears to be regulated transcriptionally. Several sig-
naling pathways involved in Survivin modulation have been 
identified, including Spl transcription factor (14), TCF/~ 
catenin (26), tumor suppressor p53 (23), Smad/BMP-7 sig-
naling ( 49), P13 kinase/ Akt signaling (9), Stat3 signaling (35) 
and IGF-1/mTOR signaling ( 46). Although strategies to 
lower Survivin levels have been pursued for rational cancer 
therapy, the molecular mechanisms controlling Survivin 50 
expression in tumors have not been completely elucidated 
45 17-3p) and resides in intron 3 of the C13orf25 gene at 
13q31.3. It has been observed that miR-17-92 cluster is fre-
quently over-expressed in human cancers (20, 21 ). Recently, 
another group has reported that mir-17-92 cluster is directly 
regulated by c-myc (10). 
Among 6 miRNAs that decreased the Survivin promoter 
activity, miR-34a is commonly deleted in human cancers and 
directlytransactivated byp53 (7, 40). InactivationofmiR-34a 
strongly attenuates p53-mediated apoptosis, while over-ex-
pression of miR-34a mildly promotes apoptosis ( 40). This is 
55 consistent with our results that miR-34a decreased Survivin 
( 46). miRNAs are newly discovered regulators of gene 
expression that are implicated in many processes, such as cell 
proliferation, apoptosis, metabolism, cell differentiation and 
morphogenesis. Currently, it is not known whether miRNAs 
are involved in the regulation of Survivin promoter activity 
via various Survivin transcriptional factors. We therefore 
screened for potential miRNAs involved in the activation 
and/or inactivation of Survivin promoter activity using a 
miRNA over-expression library containing 254 miRNAs. To 60 
perform a quick high-throughput screen, we constructed a 
human Survivin promoter-driven F. luc reporter vector, pSur-
vivin-F.Luc, and co-transfected A549 human lung cancer 
cells with the miRNA over-expression library and pRL-TK 
normalization vector. The cells were lyzed after a 48 h after 65 
transfection for a dual-luciferase assay. Compared to the 
negative control vector of pCMV-mU6-shCon, any miRNA 
promoter activity. 
Collectively, we demonstrated an alternative approach to 
construct shRNA/miRNA vectors at a greatly reduced cost 
with high efficacy. We estimate that this method could save 
over 65% of the cost of primer synthesis and DNA sequenc-
ing. It is extremely useful in generating shRNA libraries at a 
genome scale. We also reported the construction of a human 
miRNAs expression library and screening of potential miR-
NAs involved in Survivin gene regulation. The availability of 
the miRNA library as well as methods for high-throughput 
assay makes it possible to identify miRNAs involved in apo-
ptosis, phagocytosis, cell proliferation, cell cycle, p53-medi-
US 8,795,988 B2 
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ated senescence, cell morphogenesis, cytokinesis and cellular 
signaling. This will ultimately lead to a greater understanding 
of the cellular processes as well as reveal key pathways that 
might be exploited for disease detection, prevention or treat-
ment (8). 
Thus, the present invention is well adapted to carry out the 
objectives and attain the ends and advantages mentioned 
above as well as those inherent therein. While presently pre-
ferred embodiments have been described for purposes of this 
disclosure, numerous changes and modifications will be 10 
apparent to those of ordinary skill in the art. Such changes and 
modifications are encompassed within the spirit of this inven-
tion as defined by the claims. 
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<223> OTHER INFORMATION, synthetic 10-nucleotide loop sequence 
<400> SEQUENCE, 1 
cttcctgtca 
<210> SEQ ID NO 2 
<211> LENGTH, 11 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 11-nucleotide loop sequence 
<400> SEQUENCE, 2 
gtgtgctgtc c 
10 
11 
<210> SEQ ID NO 3 
<211> LENGTH, 19 
<212> TYPE, DNA 
19 
<213> ORGANISM, Artificial 
<220> FEATURE, 
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-continued 
<223> OTHER INFORMATION, synthetic 19 nucleotide loop sequence 
<400> SEQUENCE, 3 
tagtgaagcc acagatgta 
<210> SEQ ID NO 4 
<211> LENGTH, 10 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 10 nucleotide annealing region 
<400> SEQUENCE, 4 
gaagccacag 
<210> SEQ ID NO 5 
<211> LENGTH, 29 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer; n at 
positions 16-20 represents a, t, c or g; the total number of n's 
varies from 1 to 5 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (16) .. (20) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 5 
cctggtctca caccgnnnnn ttcaagaga 
<210> SEQ ID NO 6 
<211> LENGTH, 28 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer; n at 
positions 15-19 represents a, t, c or g; the total number of n's 
varies from 1 to 5 
<220> FEATURE, 
<221> NAME/KEY, misc_feature 
<222> LOCATION, (15) .. (19) 
<223> OTHER INFORMATION, n is a, c, g, or t 
<400> SEQUENCE, 6 
cctggtctca aaaannnnnt ctcttgaa 
<210> SEQ ID NO 7 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic sequencing primer 
<400> SEQUENCE, 7 
ggactatcat atgcttaccg 
<210> SEQ ID NO 8 
<211> LENGTH, 32 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
20 
19 
10 
29 
28 
20 
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21 
-continued 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 8 
caccgcggat cgatccgacg ccgccatctc ta 
<210> SEQ ID NO 9 
<211> LENGTH, 43 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 9 
cttcgaagaa ttcccgggtc tctcaaacaa ggcttttctc caa 
<210> SEQ ID NO 10 
<211> LENGTH, 10 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic 10 nucleotide loop sequence 
<400> SEQUENCE, 10 
cttcctgtca 
<210> SEQ ID NO 11 
<211> LENGTH, 14 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, segment of synthetic oligonucleotide primer 
<400> SEQUENCE, 11 
caaggtctca tttg 
<210> SEQ ID NO 12 
<211> LENGTH, 10 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, segment of synthetic ologonucleotide primer 
<400> SEQUENCE, 12 
cttcctgtca 
<210> SEQ ID NO 13 
<211> LENGTH, 12 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, segment of synthetic oligonucleotide primer 
<400> SEQUENCE, 13 
gagttcgaaa aa 
<210> SEQ ID NO 14 
<211> LENGTH, 10 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, segment of synthetic oligonucletoide primer 
<400> SEQUENCE, 14 
tgacaggaag 
22 
32 
43 
10 
14 
10 
12 
10 
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-continued 
<210> SEQ ID NO 15 
<211> LENGTH, 20 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucletide primer 
<400> SEQUENCE, 15 
acatgatagg cttggatttc 
<210> SEQ ID NO 16 
<211> LENGTH, 35 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 16 
caccgaggcc gctggccata gaaccagaga agtga 
<210> SEQ ID NO 17 
<211> LENGTH, 32 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 17 
taactagtcc acctctgcca acgggtcccg cg 
<210> SEQ ID NO 18 
<211> LENGTH, 30 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 18 
caccgcggcc gcgtataggg ctgtctggga 
<210> SEQ ID NO 19 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide primer 
<400> SEQUENCE, 19 
ggactagtct gcagcctggg tac 
<210> SEQ ID NO 20 
<211> LENGTH, 21 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic oligonucleotide 
<400> SEQUENCE, 20 
gcacaagctg gagtacaact a 
60 
What is claimed is: 
1. A method for making an shRNA expression vector, 
comprising the steps of 
a. providing first and second DNA oligonucleotide primers, 65 
wherein 
20 
35 
32 
30 
23 
21 
i) said first DNA oligonucleotide primer comprises 
sequences encoding 
at a 3' end, a first RNA loop sequence; 
at a 5' end, a first restriction enzyme recognition 
sequence; and 
US 8,795,988 B2 
25 26 
c. filling in single strand segments of said annealed structure 
to form a double-strand structure; 
d. cleaving said double-strand structure using restriction 
enzymes that recognize said first and said second restriction 
a first RNA stem sequence, wherein in said first DNA 
oligonucleotide primer, said first RNA stem sequence 
is located between said first RNA loop sequence and 
said first restriction enzyme recognition sequence; 
and 
ii) said second DNA oligonucleotide primer comprises 
sequences encoding 
5 enzyme recognition sequences, to form a structure with a 3' 
overhang and a 5' overhang; and, 
a second RNA loop sequence that is complementary to 
said first RNA loop sequence; 
10 
at a 3' end, a second restriction enzyme recognition 
sequence; and 
at a 5' end, a second RNA stem sequence, wherein said 
second RNA stem sequence is located between said 
second RNA loop sequence and said second restric- 15 
tion enzyme recognition sequence in said second 
DNA oligonucleotide primer; 
b. annealing said first RNA loop sequence and said RNA loop 
sequence to form an annealed structure; 
e. ligating said structure with a 3' overhang and a 5' overhang 
into an expression vector to form an shRNA expression vec-
tor; 
and wherein said first RNA loop sequence and said second 
RNA loop sequence are 8-10 Nucleotides in length. 
2. The method of claim 1, wherein said first and second 
DNA oligonucleotide primer each comprise 50 or fewer 
nucleotides. 
3. The method of claim 1, wherein said first and second 
restriction enzyme recognition sequences are the same. 
4. The method of claim 1, wherein said second RNA stem 
sequence is identical to said first RNA stem sequence. 
* * * * * 
